of 19 minutes and a terminal half-life of 5 hours.In man, DTlC is extensively degraded. Extravasation of the drug subcutaneously during intravenous administration may result in tissue damage and severe pain. The plasma half-life was increased in human patients with hepatic and renal dysfunction. Rarely, photosensitivity reactions may occur.Give supportive treatment and monitor blood cell counts.The recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Studies have demonstrated this agent to have a carcinogenic and teratogenic effect when used in animals. There are a number of minor toxicities that are infrequently noted. DTIC enters the CNS only to a limited extent: after 10 min the CSF : plasma ratio is 1 : 7. The most common toxicity for injectable dacarbazine is hemopoietic (bone marrow) depression. Hepatic toxicity accompanied by hepatic vein thrombosis and hepatocellular necrosis resulting in death, has been reported. Hepatic necrosis has also been reported. Patients have experienced an influenza-like syndrome of fever to 39°C, myalgias and malaise. There is no evidence from toxicity studies that Rebetol induces liver enzymes. During this period of time, Anorexia, nausea, and vomiting are the most frequently reported adverse reactions. J. Australia 1: 426–428, 1983.11. The physician must weigh the possible therapeutic benefits against the risks of toxicity. It is recommended that DTIC-Dome (dacarbazine) be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. 83-2621. Cancer Treatment Reports 60: 149–152, 1976.You are encouraged to report negative side effects of prescription drugs to the FDA. Preexisting hepatic disease or renal impairment can cause accumulation of the drug worsening dacarbazine's toxicity. The vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. Dacarbazine is an anticancer agent. Available for Android and iOS devices. The resulting solution contains 10 mg/mL of Dacarbazine having a pH of 3.0 to 4.0. Breastfeeding. Costanza, M.E., et al. have experienced an Erythematous and urticarial rashes have been observed infrequently after administration It must be assumed that an increased risk for teratogenic effects exists in humans. Visit the Copyright © 2020 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. Hemopoietic toxicity may warrant temporary suspension or cessation of therapy with dacarbazine for injection. The incidence of such reactions has been low; approximately 0.01% of patients treated. The drug is reconstituted with normal saline or sterile water to produce a 10-mg/mL solution. This toxicity has been observed mostly when dacarbazine … This toxicity has been observed mostly when dacarbazine … for safe handling of antineoplastic agents, Med. These symptoms occur usually after large single doses, may last for several days, and they may occur with successive treatments.Alopecia has been noted as has facial flushing and facial paresthesia.

It can be administered as a slow IV push or by infusion over 15–30 minutes.Myelosuppression, primarily represented by leukopenia, is the dose-limiting toxic effect.

for 5 days.

Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. Therefore, there is a minimal potential for P450 enzyme-based interactions. or sodium chloride injection, U.S.P., the resulting solution may be stored at 4°C for up to 24 hours or at normal room conditions for up to 8 hours.Procedures for proper handling and disposal of anticancer drugs should be considered. Clinical Use.

This toxicity has been observed mostly when Dacarbazine has been administered concomitantly with other anti-neoplastic drugs; however, it has also been reported in some patients treated with Dacarbazine alone.Anaphylaxis can occur following the administration of Dacarbazine.Hospitalization is not always necessary but adequate laboratory study capability must be available.

Women of child-bearing potential have to use effective contraception during treatment.